ARTICLES BY THIS AUTHOR
- 8/24/2021
IBSA intros new dosing options for Tirosint-SOL
With the addition of three new dosage strengths, Tirosint-SOL is now available in 15 dosage strengths. - 8/24/2021
APhA Foundation announces 2021 Pinnacle Award recipients
Winners were selected from across the industry in three categories. - 8/23/2021
Hy-Vee offering flu shots at pharmacies
Hy-Vee is offering the flu vaccine at more than 275 pharmacy locations, with no appointment or prescription necessary. - 8/23/2021
Camber opens new headquarters in New Jersey
Camber now has two locations in Piscataway, N.J., along with other distribution centers in New York and Tennessee. - 8/23/2021
Zydus Cadila gets FDA permission for generic Xeljanz
Tofacitinib extended-release tablets are indicated to treat moderate to severely active rheumatoid arthritis in those whom methotrexate did not work well or cannot be tolerated. - 8/23/2021
Pharmacy orgs urge HHS to authorize pharmacists to provide COVID-19 prophylaxis treatment
The efforts from pharmacy organizations follow the Food and Drug Administration recently authorizing the first post-exposure prophylaxis for COVID-19 emergency use. - 8/23/2021
IQVIA’s Long, Biggs offer pharmacy trends rundown on 2nd day of 2021 NACDS Total Store Expo
IQVIA’s Doug Long and Scott Biggs weighed in on trends, issues and forecasts for the pharmacy industry as the country begins to emerge from the pandemic and navigate a new normal. - 8/23/2021
Solaris obtains FDA green light for generic Clindagel
Clindagel has a market value of roughly $31 million for the 12 months ending June 2021, according to IQVIA. - 8/23/2021
Cardinal Health expands DE&I efforts with talent strategy
Cardinal Health said it intends to increase the company's global leadership representation of women, as well as African American and Black, Asian, Latinx, Indigenous and all other ethnically diverse groups in leadership roles. - 8/22/2021
FDA gives green light for Keytruda plus Lenvima combination
The FDA's approval of Keytruda plus Lenvima provides a first-line treatment of adult patients with advanced renal cell carcinoma, the company said.